Literature DB >> 18338567

[In vitro and in vivo biodegradation of sustained-release vehicle poloxamer 407 in situ gel].

Hongyun Feng1, Jianjun Sun, Ping Jiang.   

Abstract

OBJECTIVE: To observe the biodegradation of poloxamer 407 gel in acoustic capsule in vitro and in vivo, and to explore the applied perspective in the local drug delayed-release treatment for inner ear disorders.
METHOD: Weighing the remained amount of poloxamer 407 gel at 37 degrees C at fixation time interval. The right ears of 15 healthy guinea pigs as experimental group were perfused with 20% poloxamer 407 solution 100 microl in round window niche, the left ears as control group with normal saline. The histology of bullae at 7, 14, 28, 49 days after perfusion was examined by means of serial section after paraffin imbedding. RESULT: The degraded amount were 20% and 25% in two groups respectively. The poloxamer 407 gel at 37 degrees C after 7 weeks was (78.89 +/- 13.10) microg and (75.32 +/- 8.94) microg respectively. The poloxamer gel in bullae was almost biodegraded and discharged 49 days after perfusion, only few gel remained in the middle ear cavity under light microscope. The morphology of the mucosa of middle ear cavity and round window membrane were not significantly damaged after poloxamer 407 perfusion.
CONCLUSION: Poloxamer 407 biodegraded slowly, but it could be biodegraded in vivo or discharged via eustachian tube, and caused no inflammation and immunologic rejection on the middle ear cavity. Thus, poloxamer 407 gel is suitable for the short-time sustained-release medical treatment in the inner ear diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18338567

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1001-1781


  3 in total

1.  The effectiveness of poloxamer 407-based new anti-adhesive material in a laminectomy model in rats.

Authors:  Chang Hun Yu; Jae Hyup Lee; Hae-Ri Baek; Hwa Nam
Journal:  Eur Spine J       Date:  2011-12-10       Impact factor: 3.134

2.  Effectiveness and Feasibility of Injectable Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 for Anterior Lumbar Interbody Fusion at the Lumbosacral Junction in Adult Spinal Deformity Surgery: A Clinical Pilot Study.

Authors:  Sang-Kyu Im; Jung-Hee Lee; Ki Young Lee; Seung-Jin Yoo
Journal:  Orthop Surg       Date:  2022-05-27       Impact factor: 2.279

3.  Development of thermosensitive poloxamer 407-based microbubble gel with ultrasound mediation for inner ear drug delivery.

Authors:  Ai-Ho Liao; Cheng-Ping Shih; Ming-Wei Li; Yi-Chun Lin; Ho-Chiao Chuang; Chih-Hung Wang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.